Cara Therapeutics, Inc. Overview
Pro stress-test →Cara Therapeutics is a clinical-stage biopharmaceutical company specializing in novel therapeutics for chronic pruritus and pain by targeting peripheral kappa opioid receptors. The company's lead commercialized product is KORSUVA (difelikefalin) injection, FDA-approved for treating moderate-to-severe pruritus in hemodialysis patients, with an oral formulation in Phase II/III trials for neuropathic pruritus.
Strategic Profile
Pro stress-test →Cara leverages a differentiated mechanism targeting non-scheduled kappa opioid receptors, offering an alternative to traditional opioids without systemic side effects. The company has established partnerships with major pharma (Vifor Fresenius, Maruishi, Chong Kun Dang) for geographic expansion and commercial development, positioning itself uniquely in an underserved market with limited treatment options.
Competitive Landscape
Pro stress-test →Cara operates in a specialized pruritus treatment market with limited direct competitors. The company competes with dermatological and pain management therapies that address itch symptoms through different mechanisms. Major players in adjacent pain/inflammation spaces (Allergan, Pfizer, Johnson & Johnson) represent indirect competition, though few have specific pruritus programs targeting kappa receptors.
Industry Context
Cara Therapeutics, Inc. operates in Biopharmaceuticals / Specialty Therapeutics.
Key facts
Founded: 2004 · Headquarters: Stamford, Connecticut · Market cap: $38M